## Ana Carneiro

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/3266311/ana-carneiro-publications-by-year.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30	1,291	14	33
papers	citations	h-index	g-index
33 ext. papers	1,892 ext. citations	6.1 avg, IF	4.17 L-index

#	Paper	IF	Citations
30	Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to Fcfiib, in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or Is Refractory to Rituximab. <i>Blood</i> , <b>2021</b> , 138, 1354-1354	2.2	
29	Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004 <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 9504-9504	2.2	13
28	A first-in-human, multicenter, open-label, phase 1 study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2646-2646	2.2	1
27	Surgery of metastatic melanoma after systemic therapy - the SUMMIST trial: study protocol for a randomized controlled trial. <i>Acta Oncolgica</i> , <b>2021</b> , 60, 52-55	3.2	2
26	The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma. <i>Nature Communications</i> , <b>2021</b> , 12, 5155	17.4	16
25	Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma. <i>Molecular Oncology</i> , <b>2020</b> , 14, 933-950	7.9	16
24	Tertiary lymphoid structures improve immunotherapy and survival in melanoma. <i>Nature</i> , <b>2020</b> , 577, 567	I- <u>\$</u> 6.5 <sub>4</sub>	542
23	The Role of PTEN Loss in Immune Escape, Melanoma Prognosis and Therapy Response. <i>Cancers</i> , <b>2020</b> , 12,	6.6	12
22	17-BI-1206-02 Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to Fcgriib, in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or Is Refractory to Rituximab. <i>Blood</i> , <b>2020</b> , 136, 36-37	2.2	
21	A first-in-human phase I study in patients with advanced and/or refractory solid malignancies to evaluate the safety of ATOR-1015, a CTLA-4 x OX40 bispecific antibody <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3061-3061	2.2	3
20	Human G-MDSCs are neutrophils at distinct maturation stages promoting tumor growth in breast cancer. <i>Life Science Alliance</i> , <b>2020</b> , 3,	5.8	8
19	The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in Melanoma. <i>Cell Reports</i> , <b>2019</b> , 27, 3573-3586.e7	10.6	36
18	A Population-Based Comparison of the AJCC 7th and AJCC 8th Editions for Patients Diagnosed with Stage III Cutaneous Malignant Melanoma in Sweden. <i>Annals of Surgical Oncology</i> , <b>2019</b> , 26, 2839-2	8 <del>45</del>	8
17	Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study. <i>BMC Cancer</i> , <b>2019</b> , 19, 415	4.8	33
16	A first-in-human, multicenter, open label, phase I study in patients with advanced and/or refractory solid malignancies to evaluate the safety of intravenously administered ATOR-1015 <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS2653-TPS2653	2.2	
15	Rescue Effect Inherited in Colony Formation Assays Affects Radiation Response. <i>Radiation Research</i> , <b>2018</b> , 189, 44-52	3.1	7
14	Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. <i>Cancer Immunology, Immunotherapy,</i> <b>2017</b> , 66, 581-592	7.4	141

## LIST OF PUBLICATIONS

13	NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics. <i>Molecular Oncology</i> , <b>2017</b> , 11, 438-451	7.9	73
12	Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172) <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 9524-9524	2.2	14
11	Multiregion Whole-Exome Sequencing Uncovers the Genetic Evolution and Mutational Heterogeneity of Early-Stage Metastatic Melanoma. <i>Cancer Research</i> , <b>2016</b> , 76, 4765-74	10.1	70
10	Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172)  Journal of Clinical Oncology, <b>2016</b> , 34, 9526-9526	2.2	2
9	Molecular stratification of metastatic melanoma using gene expression profiling: Prediction of survival outcome and benefit from molecular targeted therapy. <i>Oncotarget</i> , <b>2015</b> , 6, 12297-309	3.3	102
8	Distinct gene expression profiles in ovarian cancer linked to Lynch syndrome. <i>Familial Cancer</i> , <b>2014</b> , 13, 537-45	3	11
7	Discovery-based protein expression profiling identifies distinct subgroups and pathways in leiomyosarcomas. <i>Molecular Cancer Research</i> , <b>2014</b> , 12, 1729-39	6.6	3
6	Prognostic value of proliferation in pleomorphic soft tissue sarcomas: a new look at an old measure. <i>Human Pathology</i> , <b>2012</b> , 43, 2247-54	3.7	1
5	A prognostic model for soft tissue sarcoma of the extremities and trunk wall based on size, vascular invasion, necrosis, and growth pattern. <i>Cancer</i> , <b>2011</b> , 117, 1279-87	6.4	42
4	Ezrin expression predicts local recurrence and development of metastases in soft tissue sarcomas. <i>Journal of Clinical Pathology</i> , <b>2011</b> , 64, 689-94	3.9	19
3	Indistinguishable genomic profiles and shared prognostic markers in undifferentiated pleomorphic sarcoma and leiomyosarcoma: different sides of a single coin?. <i>Laboratory Investigation</i> , <b>2009</b> , 89, 668-	<b>75</b> <sup>5.9</sup>	36
2	Prognostic impact of array-based genomic profiles in esophageal squamous cell cancer. <i>BMC Cancer</i> , <b>2008</b> , 8, 98	4.8	63
1	Genetic profiling differentiates second primary tumors from metastases in adult metachronous soft tissue sarcoma. <i>Sarcoma</i> , <b>2008</b> , 2008, 431019	3.1	2